How to manage hemostasis in patients with liver disease during interventions

2.

Drolz

A

,

Horvatits

T

,

Roedl

K

, et al.

Coagulation parameters and major bleeding in critically ill patients with cirrhosis

.

Hepatology

.

2016

;

64

(

2

):

556

-

568

.

doi:10.1002/hep.28628.

3.

Ow

TW

,

Fatourou

E

,

Rabinowich

L

, et al.

Prevalence of bleeding and thrombosis in critically ill patients with chronic liver disease

.

Thromb Haemost

.

2022

;

122

(

6

):

1006

-

1016

.

doi:10.1055/a-1667-7293.

4.

Northup

PG

,

Garcia-Pagan

JC

,

Garcia-Tsao

G

, et al.

Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases

.

Hepatology

.

2021

;

73

(

1

):

366

-

413

.

doi:10.1002/hep.31646.

5.

Villa

E

,

Bianchini

M

,

Blasi

A

, et al.

EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis

.

J Hepatol

.

2022

;

76

(

5

):

1151

-

1184

.

doi:10.1016/j.jhep.2021.09.003.

6.

Roberts

LN

,

Lisman

T

,

Stanworth

S

, et al.

Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH

.

J Thromb Haemost

.

2022

;

20

(

1

):

39

-

47

.

doi:10.1111/jth.15562.

7.

O'Shea

RS

,

Davitkov

P

,

Ko

CW

, et al.

AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis

.

Gastroenterology

.

2021

;

161

(

5

):

1615

-

1627.e1

.

doi:10.1053/j.gastro.2021.08.015.

. https://www.bsir.org/media/resources/IR_BLEEDING_RISK_GUIDANCE_FINAL_BSIR_BSH_2022.pdf.

8.

Bent

,

C

,

Das

,

R

,

Gomez

,

K

,

Lester

,

WB

;

SIR Safety and Quality Committee

;

BSH Haemostasis and Thrombosis Task Force

.

Interventional Radiology Procedure Bleeding Risk Guidance

.

2022

. Accessed

16

April

2023

9.

Bissonnette

J

,

Riescher-Tuczkiewicz

A

,

Gigante

E

, et al.

Predicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: a prospective analysis of 302 procedures

.

J Thromb Haemost

.

2022

;

20

(

12

):

2786

-

2796

.

doi:10.1111/jth.15888.

10.

Lisman

T

.

How to assess hemostasis in patients with advanced chronic liver disease

.

Hematology Am Soc Hematol Educ Program

.

2023

:in press.

11.

Ewe

K

.

Bleeding after liver biopsy does not correlate with indices of peripheral coagulation

.

Dig Dis Sci

.

1981

;

26

(

5

):

388

-

393

.

doi:10.1007/BF01313579.

12.

Zanetto

A

,

Rinder

HM

,

Senzolo

M

,

Simioni

P

,

Garcia-Tsao

G

.

Reduced clot stability by thromboelastography as a potential indicator of procedure- related bleeding in decompensated cirrhosis

.

Hepatol Commun

.

2020

;

5

(

2

):

272

-

282

.

doi:10.1002/hep4.1641.

13.

Campello

E

,

Zanetto

A

,

Bulato

C

, et al.

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure

.

Liver Int

.

2021

;

41

(

10

):

2455

-

2466

.

doi:10.1111/liv.15001.

14.

Lin

S

,

Wang

M

,

Zhu

Y

, et al.

Hemorrhagic complications following abdominal paracentesis in acute on chronic liver failure: a propensity score analysis

.

Medicine

.

2015

;

94

(

49

):

e2225

.

doi:10.1097/md.0000000000002225.

15.

Shenoy

A

,

Louissaint

J

,

Shannon

C

,

Tapper

EB

,

Lok

AS

.

Viscoelastic testing prior to non-surgical procedures reduces blood product use without increasing bleeding risk in cirrhosis

.

Dig Dis Sci

.

2022

;

67

(

11

):

5290

-

5299

.

doi: 10.1007/s10620-021-07376-6

.

16.

Rocha

LL

,

Neto

AS

,

Pessoa

CMS

, et al.

Comparison of three transfusion protocols prior to central venous catheterization in patients with cirrhosis: a randomized controlled trial

.

J Thromb Haemost

.

2020

;

18

:

560

-

570

.

doi:10.1111/jth.14672.

17.

Roberts

LN

,

Lisman

T

,

Stanworth

S

, et al.

“Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH”: reply

.

J Thromb Haemost

.

2022

;

20

(

11

):

2713

-

2714

.

doi: 10.1111/jth.15859

.

18.

Tonon

M

,

Rosi

S

,

Gambino

CG

, et al.

Natural history of acute kidney disease in patients with cirrhosis

.

J Hepatol

.

2021

;

74

(

3

):

578

-

583

.

doi:10.1016/j.jhep.2020.08.037.

19.

Hung

A

,

Garcia-Tsao

G

.

Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis

.

Liver Int

.

2018

;

38

(

8

):

1437

-

1441

.

doi:10.1111/liv.13712.

20.

Zanetto

A

,

Northup

P

,

Roberts

L

,

Senzolo

M

.

Haemostasis in cirrhosis: understanding destabilising factors during acute decompensation

.

J Hepatol

.

2023

;

78

(

5

):

1037

-

1047

.

doi:10.1016/j.jhep.2023.01.010.

21.

Montalto

P

,

Vlachogiannakos

J

,

Cox

DJ

,

Pastacaldi

S

,

Patch

D

,

Burroughs

AK

.

Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study

.

Journal of Hepatology

.

2002

;

37

(

4

):

463

-

470

.

doi:10.1016/s0168-8278(02)00208-8.

22.

Lisman

T

,

Arefaine

B

,

Adelmeijer

J

, et al.

Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease

.

J Thromb Haemost

.

2021

;

19

(

1

):

85

-

95

.

doi:10.1111/jth.15112.

23.

Douketis

JD

,

Spyropoulos

AC

,

Murad

MH

, et al.

Perioperative management of antithrombotic therapy

.

CHEST

.

2022

;

162

(

5

):

e207

-

e243

.

doi:10.13039/100009776.

24.

Spyropoulos

AC

,

Brohi

K

,

Caprini

J

, et al.

Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk

.

J Thromb Haemost

.

2019

;

17

(

11

):

1966

-

1972

.

doi:10.1111/jth.14598.

25.

Tosetti

G

,

Farina

E

,

Caccia

R

, et al.

Preprocedural prophylaxis with blood products in patients with cirrhosis: results from a survey of the Italian Association for the Study of the Liver (AISF)

.

Dig Liver Dis

.

2022

;

54

(

11

):

1520

-

1526

.

doi:10.1016/j.dld.2022.03.017.

26.

Janko

N

,

Majeed

A

,

Clements

W

, et al.

Wide variation in pre-procedural blood product transfusion practices in cirrhosis: a national multidisciplinary survey

.

Hepatol Commun

.

2023

;

7

(

5

):

e0147

.

doi:10.1097/HC9.0000000000000147.

27.

Rassi

AB

,

d'Amico

EA

,

Tripodi

A

, et al.

Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation

.

J Hepatol

.

2020

;

72

(

1

):

85

-

94

.

doi:10.1016/j.jhep.2019.09.008.

28.

von Meijenfeldt

FA

,

van den Boom

BP

,

Adelmeijer

J

,

Roberts

LN

,

Lisman

T

,

Bernal

W

.

Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease

.

J Thromb Haemost

.

2021

;

19

:

664

-

676

.

doi:10.1111/jth.15185.

. https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked-V3-November.pdf.

29.

Narayan

S

(Ed),

Poles

D

, et al;

Serious Hazards of Transfusion (SHOT) Steering Group

.

The 2021 Annual SHOT Report

.

2022

. Accessed

15th

April

2022

30.

Green

L

,

Bolton-Maggs

P

,

Beattie

C

, et al.

British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding

.

Br J Haematol

.

2018

;

181

(

1

):

54

-

67

.

doi:10.13039/501100000272.

31.

Zimmon

DS

,

Kessler

RE

.

The portal pressure-blood volume relationship in cirrhosis

.

Gut

.

1974

;

15

(

2

):

99

-

101

.

doi:10.1136/gut.15.2.99.

32.

Mohanty

A

,

Kapuria

D

,

Canakis

A

, et al.

Fresh frozen plasma transfusion in acute variceal haemorrhage: results from a multicentre cohort study

.

Liver Int

.

2021

;

41

(

8

):

1901

-

1918

.

doi:10.1111/liv.14936.

33.

Evans

CR

,

Cuker

A

,

Crowther

M

,

Pishko

AM

.

Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: a systematic review

.

Res Pract Thromb Haemost

.

2022

;

6

(

4

):

e12724

.

doi:10.13039/100005881.

34.

Lisman

T

,

Kleiss

S

,

Patel

VC

, et al.

In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis

.

Liver Int

.

2018

;

38

(

11

):

1988

-

1996

.

doi:10.13039/501100007477

.

35.

Latona

A

,

Hill

K

,

Connelly

A

,

Stuart

K

,

Wood

P

.

Prothrombinex(R)-VF in chronic liver disease: friend or foe?

Emerg Med Australas

.

2023

;

35

(

1

):

89

-

96

.

doi:10.1111/1742-6723.14058.

36.

Bosch

J

,

Thabut

D

,

Bendtsen

F

, et al.

Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial

.

Gastroenterology

.

2004

;

127

(

4

):

1123

-

1130

.

doi:10.1053/j.gastro.2004.07.015.

37.

Bosch

J

,

Thabut

D

,

Albillos

A

, et al.

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial

.

Hepatology

.

2008

;

47

(

5

):

1604

-

1614

.

doi:10.1002/hep.22216.

38.

Lodge

JPA

,

Jonas

S

,

Jones

RM

, et al.

Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation

.

Liver Transpl

.

2005

;

11

(

8

):

973

-

979

.

doi:10.1002/lt.20470.

39.

Planinsic

RM

,

van der Meer

J

,

Testa

G

, et al.

Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease

.

Liver Transpl

.

2005

;

11

(

8

):

895

-

900

.

doi:10.1002/lt.20458.

40.

Hugenholtz

GCG

,

Macrae

F

,

Adelmeijer

J

, et al.

Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen

.

J Thromb Haemost

.

2016

;

14

(

5

):

1054

-

1066

.

doi:10.13039/501100000274.

41.

Budnick

IM

,

Davis

JPE

,

Sundararaghavan

A

, et al.

Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically ill cirrhosis patients

.

Thromb Haemost

.

2021

;

121

(

10

):

1317

-

1325

.

doi:10.1055/a-1355-3716.

42.

Nguyen-Buckley

C

,

Gao

W

,

Agopian

V

,

Wray

C

,

Steadman

RH

,

Xia

VW

.

Major thromboembolic complications in liver transplantation: the role of rotational thromboelastometry and cryoprecipitate transfusion

.

Transplantation

.

2021

;

105

(

8

):

1771

-

1777

.

doi:10.1097/tp.0000000000003427.

43.

Chapman

AR

,

Yerke

JR

,

Lumpkin

M

, et al.

Evaluation of response to high-dose intravenous vitamin K administration

.

Ann Pharmacother

.

2023

:

10600280231154246

.

doi:10.1177/10600280231154246

.

44.

HALT-IT Trial Collaborators

.

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

.

Lancet

.

2020

;

395

(

10241

):

1927

-

1936

.

doi:10.1016/S0140-6736(20)30848-5.

45.

Napolitano

G

,

Iacobellis

A

,

Merla

A

, et al.

Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia

.

Eur J Intern Med

.

2017

;

38

(

2

):

79

-

82

.

doi:10.1016/j.ejim.2016.11.007.

46.

Lindquist

I

,

Olson

SR

,

Li

A

, et al.

The efficacy and safety of thrombopoeitin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis

.

Platelets

.

2022

;

33

(

1

):

66

-

72

.

doi:10.1080/09537104.2020.1859102.

47.

Rose

PD

,

Au

M

,

Woodman

RJ

,

Tee

D

,

Chinnaratha

MA

.

Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: a systematic review and meta-analysis

.

Dig Liver Dis

.

2021

;

53

(

11

):

1396

-

1403

.

doi:10.1016/j.dld.2021.07.015.

48.

Afdhal

NH

,

Giannini

EG

,

Tayyab

G

, et al.

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

.

N Engl J Med

.

2012

;

367

(

8

):

716

-

724

.

doi:10.1056/nejmoa1110709.

49.

Peck-Radosavljevic

M

,

Simon

K

,

Iacobellis

A

, et al.

Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)

.

Hepatology

.

2019

;

70

(

4

):

1336

-

1348

.

doi:10.1002/hep.30561.

50.

Terrault

N

,

Chen

Y-C

,

Izumi

N

, et al.

Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia

.

Gastroenterology

.

2018

;

155

(

3

):

705

-

718

.

doi:10.1053/j.gastro.2018.05.025.

51.

Patel

IJ

,

Rahim

S

,

Davidson

JC

, et al.

Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions - part II: recommendations

.

J Vasc Interv Radiol

.

2019

;

30

:

1168

-

1184

.

doi:10.1016/j.jvir.2019.04.017.